Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 6, 2025Open Access

Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a pQTL-based Mendelian randomization and colocalization analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CKChristina N KushnirVTVictoria Taylor‐BatemanNDNeil M Davies

Discussion

Loading...

Member takes

Overview

Mendelian randomization analysis explored DMARD targets and their role in reducing Alzheimer's disease risk, suggesting implications for future therapies.

Key Points

  • The study investigates the connection between DMARD targets and Alzheimer's disease risk.
  • Mendelian randomization analysis revealed a 10% increase in AD risk associated with FCGR3B protein levels.
  • Only one DMARD target, FCGR3B, showed potential risk association, while others did not.
  • The findings highlight the need for further research on targeting FCGR3B to mitigate AD risk.

Cite This Study

Kushnir et al. (2025) studied this question.

synapsesocial.com/papers/689522129f4f1c896c429b6ahttps://doi.org/10.1101/2025.08.01.25332834
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Plasma proteomic associations with genetics and health in the UK Biobank2023 · 1,716 citations